Raina Setzer knows the work she does matters. That’s because she’s already seen it from the other side. Setzer, a radiochemical processing technician in Oak Ridge National Laboratory’s Isotope Processing and Manufacturing Division, joined the lab in June 2023.
Carl Dukes’ career as an adept communicator got off to a slow start: He was about 5 years old when he spoke for the first time. “I’ve been making up for lost time ever since,” joked Dukes, a technical professional at the Department of Energy’s Oak Ridge National Laboratory.
Scientist-inventors from ORNL will present seven new technologies during the Technology Innovation Showcase on Friday, July 14, from 8 a.m.–4 p.m. at the Joint Institute for Computational Sciences on ORNL’s campus.
Although blockchain is best known for securing digital currency payments, researchers at the Department of Energy’s Oak Ridge National Laboratory are using it to track a different kind of exchange: It’s the first time blockchain has ever been used to validate communication among devices on the electric grid.
Laboratory Director Thomas Zacharia presented five Director’s Awards during Saturday night's annual Awards Night event hosted by UT-Battelle, which manages ORNL for the Department of Energy.
Researchers at ORNL explored radium’s chemistry to advance cancer treatments using ionizing radiation.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
More than 50 current employees and recent retirees from ORNL received Department of Energy Secretary’s Honor Awards from Secretary Jennifer Granholm in January as part of project teams spanning the national laboratory system. The annual awards recognized 21 teams and three individuals for service and contributions to DOE’s mission and to the benefit of the nation.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.
When Sandra Davern looks to the future, she sees individualized isotopes sent into the body with a specific target: cancer cells.